Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 2365 clinical trials
featured
A Randomized, Open Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® with DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

A Randomized, Open Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® with DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  • 644 views
  • 08 Nov, 2020
  • 5 locations
featured
An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

EGFR
KIT
advanced lung cancer
tyrosine
lung carcinoma
  • 358 views
  • 08 Dec, 2020
  • 4 locations
featured
A 78-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL, both in combination with noninsulin anti-diabetic treatment, in insulin naïve subjects with type 2 diabetes.

We are currently recruiting participants for a clinical research study to evaluate the effectiveness of an investigational medication for type 2 diabetics that are naive to insulin.

diabetes
type 2 diabetes mellitus
diabetes mellitus (dm)
diabetes mellitus
type 2 diabetes
  • 0 views
  • 25 Jan, 2021
  • 1 location
featured
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

This is an open-label, nonrandomized, Phase 1/2 study to evaluate the safety and tolerability, the PK, the PD, and the efficacy (antianemic activity) of INCB000928 administered alone or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. INCB000928 tablets will be administered orally …

anemia
  • 67 views
  • 05 Oct, 2020
  • 1 location
featured
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease

The primary objectives of this study are to evaluate the safety and efficacy of filgotinib in the induction and maintenance treatment of moderately to severely active Crohn's disease (CD) in participants who are biologic-naïve and biologic-experienced. Participants who complete the study, or do not meet protocol response or remission criteria …

tumor necrosis factor
remission
maintenance treatment
vedolizumab
tumor necrosis factor alpha
  • 45 views
  • 11 Jun, 2020
  • 1 location
featured
A Phase 1b, Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With REGN2810 (Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

This is a Phase 1b, open-label, multi-center, dose-escalation trial of Pexa-Vec plus REGN2810 in patients with metastatic or unresectable renal cell carcinoma (RCC). The trial consists of a dose-escalation stage, where the maximum feasible dose of Pexa-Vec in combination with REGN2810 will be determined, followed by an expansion stage. During …

programmed cell death 1 ligand 1
clear cell renal cell carcinoma
measurable disease
renal cell cancer
karnofsky performance status
  • 0 views
  • 23 Nov, 2020
  • 3 locations
featured
A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Characterize the safety and tolerability, and evaluate Pharmacokinetics of MRTX849 in combination with TNO155 in patients with advanced solid tumor malignancies with KRAS G12C mutation. MRTX849 is an orally available small molecute inhibitor of KRASG12C. TNO155 is a selective, orally bioavailable allosteric inhibitor of wild type SHP2.

malignant solid tumor
advanced solid tumor
solid tumor
solid tumors
  • 114 views
  • 19 Feb, 2021
  • 10 locations
featured
Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-7)

This Phase 2 study evaluates the clinical activity and safety of MRTX849 in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS.

  • 0 views
  • 03 Mar, 2021
  • 11 locations
featured
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - Australia  

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept (ACE-536) …

epoetin alfa
erythropoietin
cancer
vasectomy
  • 53 views
  • 09 Feb, 2021
  • 7 locations
featured
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination with Topical Corticosteroid Treatment in Patients with Moderate-to-Severe Atopic Dermatitis.

The ADhere Study is a phase 3 clinical research study for adults and adolescents (≥ 12 to < 18 years of age and weighing ≥ 40 kg or 88 lb.) who have had atopic dermatitis (AD) for at least one year. The ADhere Study consists of three parts: a screening …

topical agents
eczema
  • 5 views
  • 05 Feb, 2021
  • 38 locations